DU145型
细胞生物学
材料科学
癌细胞
纤维连接蛋白
细胞外基质
上皮-间质转换
间充质干细胞
癌症研究
化学
下调和上调
生物
生物化学
癌症
LNCaP公司
遗传学
基因
作者
M.A. van der Pol,Hanyuan Gao,He Zhang,Olivia J George,Joseph M. Fox,Xinqiao Jia
出处
期刊:Biomaterials
[Elsevier]
日期:2023-08-01
卷期号:299: 122180-122180
被引量:1
标识
DOI:10.1016/j.biomaterials.2023.122180
摘要
Synthetic matrices with dynamic presentation of cell guidance cues are needed for the development of physiologically relevant in vitro tumor models. Towards the goal of mimicking prostate cancer progression and metastasis, we engineered a tunable hyaluronic acid-based hydrogel platform with protease degradable and cell adhesive properties employing bioorthogonal tetrazine ligation with strained alkenes. The synthetic matrix was first fabricated via a slow tetrazine-norbornene reaction, then temporally modified via a diffusion-controlled method using trans-cyclooctene, a fierce dienophile that reacts with tetrazine with an unusually fast rate. The encapsulated DU145 prostate cancer single cells spontaneously formed multicellular tumoroids after 7 days of culture. In situ modification of the synthetic matrix via covalent tagging of cell adhesive RGD peptide induced tumoroid decompaction and the development of cellular protrusions. RGD tagging did not compromise the overall cell viability, nor did it induce cell apoptosis. In response to increased matrix adhesiveness, DU145 cells dynamically loosen cell-cell adhesion and strengthen cell-matrix interactions to promote an invasive phenotype. Characterization of the 3D cultures by immunocytochemistry and gene expression analyses demonstrated that cells invaded into the matrix via a mesenchymal like migration, with upregulation of major mesenchymal markers, and down regulation of epithelial markers. The tumoroids formed cortactin positive invadopodia like structures, indicating active matrix remodeling. Overall, the engineered tumor model can be utilized to identify potential molecular targets and test pharmacological inhibitors, thereby accelerating the design of innovative strategies for cancer therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI